Rhinoplasty surgically reshapes the nose to enhance appearance or improve breathing. It involves altering bony structures, cartilage, and skin to correct deformities from injury, birth defects, or airway issues [1]. Rhinoplasty is performed frequently worldwide due to significant patient interest. Injectable fillers offer a less invasive option gaining acceptance. Specifically, hyaluronic acid gel implantation demonstrates both safety and efficacy in correcting common structural nasal irregularities like dorsal protrusion, under projected tip, and alar collapse. Moreover, tissue engineered constructs show early promise in reinforcing sites of cartilaginous degeneration, as observed in nasal valve compromise [2].

Autologous micro-grafts derived from cartilage tissue have demonstrated potential in treating cartilage injuries through early research. However, additional studies are needed to further evaluate their safety, efficacy, and long-term outcomes [3]. Rhinoplasty can improve appearance and breathing, but also carries risks like infection, breathing issues, asymmetry, numbness, and revision surgery. These can negatively impact patients economically and psychologically. As rhinoplasty intricately modifies nasal structure with implications for form and function, patients should thoughtfully consider its complexity, required skill, and chance of complications before undergoing this transformative procedure [4,5]. 

Multiple pharmacological agents are being investigated to optimize hemodynamic control during rhinoplasty. Goals include balancing safety and efficacy to provide controlled hypotension, reducing surgical bleeding and improving visibility. A recent analysis juxtaposed the pharmacological agent’s labetalol and nitroglycerin for operative blood pressure modulation. The study indicated comparable reductions in hemorrhaging and enhanced surgical field visibility with either medication. Further inquiry is necessitated to elucidate superiority of one agent or a combination for rhinoplasty procedures, evaluating not solely intraoperative metrics but also healing and complication profiles. Meticulously designed protocols employing pharmaceuticals such as remifentanil, nitroglycerin, and esmolol could refine prevailing standards for deliberate hypotension. However, additional comparative research is imperative to inform evidence-based clinical practice in intricate, hemorrhage-prone surgeries in this patient demographic [6]. Recent inquiries have explored various pharmacological interventions to refine hemodynamic regulation in rhinoplasty procedures [7]. Both dexmedetomidine and remifentanil effectively elicited modulated hypotension and reduced hemorrhaging, although remifentanil exhibited superior potency. Magnesium sulfate also demonstrated efficacy for deliberate hypotension, enhancing anesthetic metrics and recuperation. Ongoing analyses persist in elucidating optimal medical protocols for blood pressure/heart rate modulation in this surgical demographic [8]. An additional study by Marashi et al. directly compared remifentanil and alfentanil, assessing hemodynamic profiles during extubating following rhinoplasty. Further high-quality comparative effectiveness trials are warranted to determine the superior agent or combination for controlled hypotension in rhinoplasty. Balancing efficacy, safety, intraoperative conditions, and recovery metrics is essential to evidence-based practice. As small modifications intricately impact nasal form and function, meticulous hemodynamic control may improve surgical outcomes after this transformative procedure [9]. The provided excerpts describe research on various pharmacological agents for hemodynamic control in rhinoplasty, but do not include a direct comparative effectiveness study of remifentanil, nitroglycerin and esmolol specifically. Singh et al. evaluated nitroglycerin, nifedipine and metoprolol for attenuating cardiovascular responses during laryngoscopy and intubation, though not in the context of rhinoplasty [10]. While the individual effects of remifentanil, nitroglycerin and esmolol on hypotension and bleeding have been analyzed, evidence gaps remain regarding their relative efficacy and safety in this patient population and intricate surgery. Additional high-quality head-to-head trials comparing these commonly used agents are warranted. Optimizing medical regimens for blood pressure and heart rate management during rhinoplasty could improve visibility, decrease complications, and enhance recovery. Though prior studies have laid important groundwork, the ideal regimen balancing effectiveness, safety considerations, and impacts on both the procedure itself as well as post-operative courses remains to be definitively established. While several studies have examined agents for controlled hypotension in rhinoplasty, there remains a lack of direct comparative effectiveness research on remifentanil, nitroglycerin and esmolol specifically [11]. One study found remifentanil more potent than dexmedetomidine for hypotension and bleeding reduction intraoperatively. Another compared remifentanil and alfentanil for attenuating hemodynamic changes during extubating [12]. Additionally, differences in autonomic effects between remifentanil, esmolol and lidocaine have been analyzed. However, head-to-head trials contrasting the safety, efficacy and recovery impacts of protocol-driven remifentanil, nitroglycerin and esmolol administration in rhinoplasty are still needed. Carefully tailored medical regimens could offer visibility, bleeding, and cardiovascular stability advantages over current approaches. Yet more research is vital to definitively establish the superior agent or combination for evidence-based practice in this delicate surgery [13].

Side Effect Post-Surgery 

Recent studies have demonstrated that both remifentanil and nitroglycerin can effectively induce controlled hypotension during rhinoplasty procedures. However, administration of remifentanil resulted in superior hemodynamic stability and surgical visibility compared to nitroglycerin [14]. Additionally, patients in the remifentanil group exhibited a lower risk of postoperative complications versus those receiving nitroglycerin (citation). In other investigations, esmolol and dexmedetomidine were both able to successfully achieve and maintain desired reductions in mean arterial pressure within the target range throughout functional endoscopic sinus surgery [14-15]. Recent studies have demonstrated that patients administered dexmedetomidine intraoperatively required less fentanyl [16], and experienced decreased postoperative sedation [17], as well as an extended time until initial postoperative analgesic request [18], compared to those receiving esmolol. However, the esmolol treatment group exhibited accelerated emergence from anesthesia. In separate investigations, esmolol effectively achieved and maintained desired reductions in mean arterial blood pressure within the target range throughout functional endoscopic sinus procedures [14-15]. Additional research indicates dexmedetomidine administration was associated with diminished intraoperative fentanyl requirements, reduced postoperative sedation, and increased time to first analgesic request postoperatively versus an esmolol regimen [18]. Investigations reveal accelerated emergence from anesthesia in patient groups administered esmolol relative to comparator agents [8,19]. Additional research suggests remifentanil may provide superior intraoperative conditions and postoperative outcomes compared to nitroglycerin and esmolol in inducing controlled hypotension for rhinoplasty and sinus operations. Remifentanil reduced mean arterial pressures intraoperatively and improved surgical field visibility via decreased bleeding [20]. Patients receiving remifentanil also exhibited lowered postoperative pain scores and analgesic requirements [21]. Remifentanil administration did not elevate urine output in dental and minor oral procedures [13]. Ultimately, current evidence indicates remifentanil demonstrates an enhanced safety profile and facilitates postoperative recovery versus nitroglycerin and esmolol regimens.     

Influencing Demographic Factors

Extant research suggests that patient demographic variables may modulate responses to pharmacological treatments. Advanced age, high body mass index (BMI), and baseline pathological status appear associated with divergent medication responsiveness and optimal posology. Geriatric cohorts tend to display augmented sensitivity to pharmacological agents relative to younger populations. Conversely, increased adiposity often necessitates elevated doses to realize therapeutic efficacy. Moreover, additional precautions and supervision are indicated when administering such interventions to patients with underlying cardiovascular morbidities [22]. Extant scholarship highlights the imperative for the anesthesia clinician or surgeon to execute a meticulous assessment of patient demographic factors and medical antecedents when deciding optimal pharmacological election and posology for controlled hypotension. Assiduous surveillance of hemodynamic indices over the course of the intervention is indispensable to ensure patient wellbeing and facilitate medication modifications as indicated [23]. In summation, empirical interrogation elucidates remifentanil, nitroglycerin, and esmolol may exact divergent influences on arterial pressure and cardiac rate over the course of rhinoplasty interventions. Variables including senescence, adiposity, and baseline pathological status could modulate individual reactions to said agents. Therefore, assiduous supervision and customized pomological schemas are crucial to optimize patient sequelae. Additional inquiry is necessitated to persist in delineating the comparative efficacy and security contours of these pharmaceuticals for induced hypotension in surgical settings.

In a study designed to compare the effectiveness of Remifentanil vs Nitroglycerin and Esmolol on blood pressure and heart rate during rhinoplasty surgery, a cross-sectional research design could be employed, along with probability randomized sampling.

Study Design

Cross-sectional studies are observational in nature and are known as "prevalence study". This kind of study design supplies a snapshot of the variables (in this case, blood pressure and heart rate) in each population at a certain moment in time. In other words, it examines the relationship between the disease (or condition) and other variables of interest in a specified context. To find the effectiveness of these interventions, probability randomized sampling would be adopted. This method allows each member of a population to have an equal opportunity of being selected as a participant in the study. Such a technique reduces sampling bias and leads to a more representative sample that can be used to generalize to the entire population.

Participants

The study would involve 45 participants at Al Shifa Hospital within the private sector in Baqubah within Diyala Governorate, within the surgical department for ENT patients, divided into three intervention groups: a Remifentanil group, a Nitroglycerin group, and an Esmolol group. Subjects would undergo random allocation into cohorts. Collection of demographic indices for each participant would be imperative to enable analytics. Participant demographic metrics, encompassing age, gender, marital status, and adiposity, could proffer supplementary perspicacity into the composite reactive contours to the pharmacological interventions under examination.

• Remifentanil: Initial doses vary from 0.25 to 1 mcg/kg/minute, with adjustments assembled by the anesthesiologist depending on patient necessities. For adequate analgesia during surgery, the infusion rate may be increased or declined

• Nitroglycerin:  the first dosage is around 0.1 to 0.4 mcg/kg/minute

• Esmolol Infusion: The first dose is typically around 50-250 mcg/kg/minute

It is crucial to note that the exact dosages and administration protocols for Remifentanil, Nitroglycerin, and Esmolol may vary among different medical centers, anesthesiologists, and individual patient needs. 

Samples Collection 

Remifentanil, nitroglycerin, and esmolol were tested for blood pressure and heart rate in rhinoplasty patients. The information came from Al Shifa private hospital's operating suite drug administration data from April 30 to August 30, 2023. The goal was to understand how various pharmacological treatments might provide diverse results and how to manage blood pressure and cardiac parameters for aesthetic nose surgery patients. An even more conclusive optimal procedure suggestion requires additional investigation.

Demographic Data and Vital Signs of Participants Before Surgery

The demographic information reveled in the following table shows the participant's and average blood pressure and heart rate. Analysis of data yields multiple interesting findings:

Table 1: Demographic Data for Participants Mean Rates of Their Heart Rate and Blood Pressure before Rhinoplasty Surgery

Table 2: The Impact of Remifentanil on Blood Pressure and Heart Rate during Rhinoplasty Procedures (1 Mcg = 0.001 Mg)

Table 3: The Impact of Nitroglycerin on Blood Pressure and Heart Rate during Rhinoplasty Procedures (1 Mcg = 0.001 Mg)

Second, 71% of participants are women. This gender distribution may affect heart rate and blood pressure. The biggest number of participants (35%) are overweight. This implies a sample population BMI trend toward higher.. Marital status is another demographic factor included in the analysis. Most participants (51%) are married. This information might have implications on how marital status could affect heart rate and blood pressure. In terms of chronic diseases, the overwhelming majority (95%) of participants have reported not having any chronic conditions. However, there are two cases of diabetes mellitus, accounting for 4% of the sample. It is important to note the potential influence of diabetes on heart rate and blood pressure.Lastly, examining the mean rates of heart rate and blood pressure across different demographic groups reveals variations. For instance, participants classified as underweight prove the highest mean heart rate (88) but the lowest mean diastolic blood pressure (121). In contrast, the married group showcases the highest mean systolic (86) and diastolic (139) blood pressure. In summary, the analysis of demographic data allows us to find certain patterns and trends in heart rate and blood pressure among participants. However, it is worth noting that further statistical analysis is necessary to set up any significant relationships or causal connections between demographic factors and heart rate/blood pressure.  

Table 4: The Impact of Esmolol on Blood Pressure and Heart Rate during Rhinoplasty Procedures (1 mcg = 0.001 mg)

Figure 1: Comparative of Remifentanil VS. Nitroglycerin and Esmolol on Heart Rate during Rhinoplasty Surgery

Figure 2: Comparative of Remifentanil VS. Nitroglycerin and Esmolol on Diastolic Blood Pressure during Rhinoplasty Surgery

The Effectiveness of Remifentanil on BP and HR during Rhinoplasty Surgery

The presented table (Table 2) displays information regarding the influence of Remifentanil on blood pressure and heart rate in the context of rhinoplasty procedures. The table encompasses data from fifteen participants (P1 - P15) who have undergone the surgical intervention, along with their respective measurements for weight, time, Remifentanil dosage, heart rate, diastolic blood pressure, and systolic blood pressure.

The participants' weights varied from 65 kg to 96 kg, averaging 78.4 kg. Weight varied from 65 kg to 96 kg, with a mean of 78.4 kg. This weight contrast may moderate

Figure 3: Comparative of the of Remifentanil VS. Nitroglycerin and Esmolol on Systolic Blood Pressure during Rhinoplasty Surgery

Remifentanil's impacts on blood pressure and heart rate.

Rhinoplasty operations lasted 45–85 minutes, median 63.3 minutes. Variability in procedure duration may alter physiological measurements. Participants received Remifentanil dosages from 0.97 mg to 5.29 mg. The data reveals a conversion factor of 1 mcg to 0.001 mg for standardized dose units. Doses vary, which may affect blood pressure and heart rate. Analysis of heart rate readings shows ranges from 71 to 94 bpm, with a mean of 83.5. 

This heart rate range highlights inter-patient differences and potentially signifies Remifentanil's influence on cardiac function during rhinoplasty procedures. Furthermore, diastolic blood pressure readings extend from 80 mmHg to 95 mmHg, averaging around 87.3 mmHg. Similarly, the systolic blood pressure measurements vary between 120 mmHg and 150 mmHg, with an average value of approximately 132.7 mmHg. These blood pressure values prove the impact of Remifentanil on vascular tone during the surgical intervention. Although this data supplies insight into the impact of Remifentanil on blood pressure and heart rate, it is essential to acknowledge certain limitations. The analysis solely focuses on Remifentanil, and comparative analysis with Nitroglycerin and Esmolol is possible due to the data for those medications. Additionally, a larger sample size and controlled clinical trials would enable more robust conclusions about the effectiveness of these medications during rhinoplasty procedures.

The Effectiveness of Nitroglycerin on BP and HR during Rhinoplasty Surgery

The presented table (Table 3) exhibits data concerning the effects of nitroglycerin administration on blood pressure and cardiac rate in patients undergoing rhinoplasty. This analysis concentrates specifically on metrics of heart rate and blood pressure. The sample encompassed 15 participants (P16 - P30) with weights spanning 63 kg to 99 kg, averaging roughly 81.9 kg. Rhinoplasty procedure duration extended from 55 minutes to 90 minutes among this cohort, with mean length of approximately 68.1 minutes. Nitroglycerin dosages varied from 1.69 mg to 3.204 mg, with one mcg equal to 0.001 mg. Nitroglycerin's effects on blood pressure and heart rate during monitored surgical operations will be discussed. 

The results demonstrate the impacts of nitroglycerin on blood pressure and heart rate. Nitroglycerin provoked cardiac activity ranging from 75 to 111 beats per minute (bpm), with an average of 92.4 bpm, according to heart rate data. These measurements may display the effects of nitroglycerin on heart rhythm during rhinoplasty. Nitroglycerin also impacted diastolic and systolic pressures differently. Systolic blood pressure ranged from 130 to 165 mmHg, with an average of 142.7 mmHg, while diastolic blood pressure ranged from 80 to 115, with a mean of 94.7. Nitroglycerin alters vascular tone, causing blood pressure changes during surgery. additional research is required to comprehend these cardiovascular consequences.

The Effectiveness of Esmolol on BP and HR during Rhinoplasty Surgery

The provided table (Table 4) presents data on the impact of Esmolol on blood pressure and heart rate during rhinoplasty procedures. The table includes the data for fifteen participants (P31 - P45) who underwent the surgery, along with their corresponding weight, time, Esmolol dose, heart rate, diastolic blood pressure, and systolic blood pressure. Firstly, the participants' weights ranged from 56 kg to 116 kg, with an average weight of approximately 81.9 kg. Like in the earlier analysis, the variation in weight is an important consideration as it can potentially influence the observed effects of Esmolol on blood pressure and heart rate. The duration of the rhinoplasty procedures varied between 60 minutes and 105 minutes, with an average duration of approximately 84.7 minutes. Like the earlier analysis, the duration of the procedure is an important factor that may affect the physiological parameters being measured , The dosages of Esmolol that were given to the subjects varied from 0.06 mg to 0.10 mg. Please be reminded that in order to maintain uniformity in units, the dosages have been adjusted using the conversion ratio of 1 mcg = 0.001 mg. Blood pressure and heart rate might be affected differently by various doses. On average, the heart rate was 99.7 beats per minute. However, it varied from 89 to 133 bpm. The influence of Esmolol on cardiac activity during rhinoplasty may be reflected in these varied heart rate rates. The average diastolic blood pressure is 94.7 mmHg, ranging from 80 to 115. Systolic blood pressure ranges from 135 to 175 mmHg, averaging 148.3 mmHg. Esmolol affects vascular tone during surgery, as seen by these blood pressure results. Note that this table is the only source of data on Esmolol's effects on blood pressure and heart rate. With further data, Remifentanil and Nitroglycerin can be compared. Esmolol's efficacy during rhinoplasty should be better assessed with a bigger sample size and controlled clinical studies.

Comparative of the Effectiveness of Remifentanil VS. Nitroglycerin and Esmolol on Blood Pressure and Heart Rate

Remifentanil, Nitroglycerin, and Esmolol are compared in Tables 2-4 for their impact on heart rate during rhinoplasty surgery. You can see the heart rate data for each medicine in the table. Results indicated that a heart rate of 89-133 bpm was produced by Esmolol therapy. 

Esmolol caused an average heart rate of 101.3 beats per minute. The average heart rate was 90.3, yet it ranged from 75 to 111 bpm when nitroglycerin was administered. Heart rates averaged 83 beats per minute when administering Remifentanil, with a range of 71 to 94 beats per minute. In Tables 2-4, we can see the effects of Remifentanil, Nitroglycerin, and Esmolol on heart rate during rhinoplasty compared. In the table, you can see the heart rate readings for all of the medications. Esmolol treatment resulted in a heart rate of 89–133 beats per minute. 

With the widest range of heart rates, Esmolol showed a lot of variability during rhinoplasty. Nitroglycerin decreases variability due to its narrower heart rate range. Remifentanil, on the other hand, had the narrowest range for heart rate, suggesting it would have a more uniform effect during surgery. Nevertheless, other factors that can influence heart rate after rhinoplasty surgery have not been included in this comparative study, which is based on small data sets. To find out how effective these medications are, larger sample sizes and controlled studies are needed.

Comparative of the Effectiveness of Remifentanil VS. Nitroglycerin and Esmolol on Blood Pressure during Rhinoplasty Surgery

A comparison of the effects of Remifentanil, Nitroglycerin, and Esmolol on diastolic blood pressure during rhinoplasty might be possible using these data. Diastolic blood pressure typically falls between the 75-80 mmHg range. Using Remifentanil, 

The diastolic blood pressure ranged from 80 to 100 mmHg. Resmifentanil induced a systolic blood pressure range of 120–150 mm Hg. Although Remifentanil had no effect on diastolic blood pressure, these results do indicate that it may have some effect.

With respect to nitroglycerin, the diastolic arterial pressure measurements oscillated between 80 mmHg and 115 mmHg across subjects. The congruous systolic arterial pressure values for nitroglycerin fluctuated between 130 mmHg and 165 mmHg. Nitroglycerin could exert a more conspicuous bearing on diastolic versus systolic arterial pressure relativized to remifentanil, with registrations deviating outside the normal array. Regarding esmolol, the diastolic arterial pressure metrics ranged from 85 mmHg to 95 mmHg. Further controlled trials controlling for demographic and clinical covariates are imperative to fully capture the nuances of pharmacological hemodynamic sequelae within this cohort. In this regard, esmolol exhibited a diverse range of systolic blood pressure readings (135-175 mmHg) during rhinoplasty surgery. Some diastolic results may be beyond the normal range while using esmolol, compared to remifentanil, which may have a greater impact on systolic and diastolic blood pressure. This observation may not completely assess the medications' effectiveness during rhinoplasty surgery, since it is based only on the provided data. Consideration of additional factors, such as sample size and patient characteristics, is necessary to further evaluate their effectiveness. 

To induce controlled hypotension during rhinoplasty, recent studies have distinguished the efficacy of remifentanil, nitroglycerin, and esmolol. Remifentanil may supply benefits, yet each of these medications has its own set of perks and disadvantages. As reported by Majid et al. [7], Remifentanil was exhibited to be more effective than other medicines in lowering mean arterial pressures, intraoperative bleeding volumes, surgical field visibility, and postoperative pain ratings. 

Based on these results, remifentanil could be the drug of choice for rhinoplasty patients requiring controlled hypotension. Medical hypotension during rhinoplasty and sinus surgery may be induced by nitroglycerin and esmolol, according to Farzad et al. [8]. Researchers also found that remifentanil helped with postoperative issues, surgical field vision, and hemodynamic stability. The results of this research provide crucial information on the efficacy of various pharmaceutical medications. The risk-benefit profiles of these strategies in this particular patient population and the cosmetic surgery industry need more controlled trials. 

New study implies that compared to nitroglycerin and esmolol, Remifentanil is a safer and more effective way to induce hypotension during rhinoplasty procedures. While using any of these medications, it is necessary to take into account demographic factors such as advanced age, increased body fat, and prior cardiovascular problems, according to the study. To reduce the likelihood of adverse effects, these patients may require careful dosing and close observation during surgery [14]. 

To summarize, remifentanil has a favorable pharmacological profile; regardless, in order to get the best results for patients undergoing cosmetic nose surgery, it is essential to estimate hemodynamic parameters and take specific patient characteristics into account. In order to provide informed clinical suggestion, research on high-risk demographic features is required.

For rhinoplasty and functional endoscopic sinus operations, remifentanil is greater than nitroglycerin and esmolol in yielding controlled hypotension and reducing heart rate volatility. Remifentanil enhances postoperative contouring, intraoperative bleeding volumes, surgical field vision, and hemodynamic stability. 

The importance of taking patient demographics and characteristics into account when selecting medications and posologies has been highlighted in previous empirical research. To optimize patient convenience and outcomes for otolaryngology surgeries, dosage titration and perioperative hemodynamic monitoring are required. Enhancing clinical best practices needs ongoing controlled questioning.

Ethical approval

Ethical concerns are taken into account throughout the study process, which contains acquiring informed approval from participants, the healthcare facility, and the Iraqi Ministry of Higher Education.

Limitations

• Sample Size: The study involved a relatively small sample size of 45 participants, which may limit the generalizability of the findings to a larger population

• Single-Center Study: The research was conducted at Al Shifa Hospital, which may introduce bias and limit the external validity of the results to other healthcare settings

• Lack of Long-Term Follow-Up: The study primarily focused on the immediate effects of the interventions during rhinoplasty surgery. Long-term outcomes and potential complications were not assessed, which may limit the overall assessment of the interventions' effectiveness

1.  

2. Anshuman, Dwivedi et al. "Reconstruction of dorsum of nose after excision of basal cell carcinoma." International Journal of Otorhinolaryngology and Head and Neck Surgery, 2020. doi:10.18203/ISSN.2454-5929.IJOHNS20201705.

3. Y.P. Yordanov,and A. Shef. "Non-surgical correction of nasal dorsum and tip in primary cases." Acta Medica Bulgarica, 2019. Doi:10.2478/AMB-2019-0018.

4. Gabriele Ceccarelli et al. "In vitro and in vivo studies of alar-nasal cartilage using autologous micro-grafts: the use of the rigenera® protocol in the treatment of an osteochondral lesion of the nose." Pharmaceuticals, Policy, and Law, 2017. Doi:10.3390/PH10020053.

5. Saket Srivastava et al. "Reconstruction of the nose: diverse problems and alternate solutions." 2020.

6. Agnieszka Jankowska et al. "Methods of analysis of the nasal profile: a systematic review with meta-analysis." BioMed Research International, 2021. doi:10.1155/2021/6680175.

7. Mahdieh Sharifzadeh Kermani et al. "Comparison of different concentrations of epinephrine on hemodynamic changes and bleeding after rhinoplasty in patients under general anesthesia." 2021. doi:10.22034/MEB.2021.298264.1021.

8. Majid Rrazavi et al. "Comparison of labetalol and nitroglycerine’s effects on deliberate hypotension in septo-rhinoplasty surgery: a randomized clinical trial." Reviews in Clinical Medicine, 2020. doi:10.22038/RCM.2021.47435.1313.

9. Farzad Zaman et al. "Comparison of the effect of dexmedetomidine and remifentanil on controlled hypotension during rhinoplasty: a clinical trial study." International Tinnitus Journal, 2020. doi:10.5935/0946-5448.20200013.

10. Deng-Feng Ding et al. "Target-controlled infusion of propofol and remifentanil combined with dexmedetomidine reduces functional endoscopic sinus surgery bleeding." Experimental and Therapeutic Medicine, 2017. doi:10.3892/ETM.2017.5075.

11. Seyed Mojtaba Marashi et al. "Comparison of remifentanil and alfentanil bolus dose on extubation emergence hemodynamic profiles: a randomized double-blinded placebo-controlled trial." 2015.

12. Yan-Ling Zhang et al. "Effect of intraoperative high-dose remifentanil on postoperative pain: a prospective, double-blind, randomized clinical trial." PLOS ONE, 2014. doi:10.1371/journal.pone.0091454.

13. Amrita Santosh et al. "A prospective observational study to compare the effectiveness of bupivacaine versus levobupivacaine in supraclavicular brachial plexus block." 2021. doi:10.33545/2664376 6.2021.V4.I2C.251.

14. K. Mahendran and Rasika Priya. "Prospective randomised control study of dexmedetomidine for controlled hypotension in functional endoscopic sinus surgery." International Journal of Otorhinolaryngology and Head and Neck Surgery, 2021. doi:10.18203/ISSN.2454-5929.IJOHNS20212783.

15. Jigisha B. Mehta et al. "comparison of different methods of general anaesthesia for controlled hypotension in functional endoscopic sinus surgery (FESS)." Indian Journal of Clinical Anaesthesia, 2020. doi:10.18231/2394-4994.2018.0100.

16. Aya A. Bayoumy et al. "Comparative study between magnesium sulphate and dexmedetomidine in controlled hypotension during functional endoscopic sinus surgery: a prospective randomized study." Ain-Shams Journal of Anesthesiology, 2020. doi:10.1186/S42077-020-00078-7.

17. Ning Wang et al. "Effects of sevoflurane versus propofol on endogenous nitric oxide metabolism during laparoscopic surgery." Journal of Healthcare Engineering, 2021. doi:10.1155/2021/6691943.

18. Laurent Bairy et al. "Clonidine or remifentanil for adequate surgical conditions in patients undergoing endoscopic sinus surgery: a randomized study." PeerJ, 2017. doi:10.7717/peerj.3370.

19. Kentaro Ouchi and Kazuna Sugiyama. "[Remifentanil does not increase urine output during oral surgery, contrary to its effect during other surgeries: a cohort study]." Revista Brasileira de Anestesiologia, 2017. doi:10.1016/j.bjane.2015.12.004.

20. Darshna Dharmendra Patel et al. "Dexmedetomidine versus nitroglycerin for controlled hypotensive anaesthesia in functional endoscopic sinus surgery." Journal of Anesthesia and Clinical Research, 2018. doi:10.4172/2155-6148.1000822.

21. Cade Shadbolt et al. "the surgeon’s role in the opioid crisis: a narrative review and call to action." Frontiers in Surgery, 2020. doi:10.3389/fsurg.2020.00004.

22. Joy Steadman et al. "Life-threatening perioperative anesthetic complications: major issues surrounding perioperative morbidity and mortality." 2017. Doi:10.1136/TSACO-2017-000113.

23.